Member Info for Doc83

SBM, the interviewer last night said RM will be on later on in the week “to tell us when we *might* get access” to it.

I think it will just be a normal chat. But maybe they will RNS trial complete and 35 days passed, and he can go into a bit more detail.

Anyway, 206p… LEAAAAAKKK! :D

Brokers with a large order to fill probably, trying to stoke up a bit of volatility! Maybe trigger a few new stop losses now that price has moved up a bit.

Thanks Matterhorn, appreciate I’m asking a lot of questions and this is very much new ground for me, so learning as I’m going along with parts of this.

Re the £2 achieved, the bid/offer spread is wider than a barn door again. But this time it’s blown out to the offer side which is nice for a change.

What are the chances that when SNG announced on 11/11 that last patient had been recruited, that the patient will have already had his 14 day course, or have been a good way through it?

The reason I ask is that to me it doesn’t make sense to announce to us last patient recruited, when that patient might pull out at the last minute or part way through for whatever reason, or for any reason just not complete the course. Then SNG would have to find another “last” patient and the RNS wouldn’t be worth the paper it was written on. Surely better to wait until after that last patient has been dosed?

Maybe I’m continuing to be hopeful of news sooner rather than later, but if that was the case, then the data will already be getting crunched…

Matml74, that would be incredible if they have seen the data. I thought we had discussed this some weeks back and concluded that no company had previously been shown their P2 data on Activ?

If they have, then that could explain why they look so happy and confident, and are recruiting like they are.

Sorry… Last patient recruited!

I think we’re probably over thinking it. They wanted him on around 1st December (I think that’s when he was presented with his knighthood), maybe to talk following last patient dosed.

The “when” bit, he says they have RM on later in the week to find out when it “might” be available.

Anyway, that’s me done for today. I might get woken up with an RNS at any time so need to be ready for it!

Yes, I agree it’s great to see Sir Stephen giving a great interview. But feet back on the ground time, we’re still ultimately waiting for the data. I’m sure the interviewer saying “when” is nothing to take too seriously.

I will still very much look forward to watching RM later this week and to see if he lets any info slip!

They’ve not seen the results though, yet!

Could the US maybe have given them a peek of the ACTIV P2 data… ;)

FFS Matml74, I was holding off unscrewing the kitchen sink but I think I’ll have to chip in my spare kidney now :D

Reasons To Invest In Synairgen:

- Previous trial results, including advancement to phase 3 in ACTIV US trial, are supportive of a positive outcome.
- 80% of phase 3 trials succeed.
- Excellent management team who have worked on this for many years.
- Recent recruitment drive to senior positions.
- Science supports the case for IFNb.
- Ingredient is a naturally occurring protein.
- Broad-spectrum antiviral, already proven (in vitro) to work on multiple variants of Covid-19.
- Different to current crop therapeutics (inhalation).
- Could provide basis for other treatments, Asthma/COPD etc.
- Brokers positive. Numis price target of £9.90, Dr Paul Cuddon experienced in covering such stocks. Finncap also positive.
- Omicron, an even more urgent need than ever for a variety of therapeutics.
- Vaccine weariness, more people becoming disillusioned with vaccines. May need to rely more on therapeutics.
- Represents a good risk/reward bet.
- Polygon/Polar taking significant stakes in Synairgen.

Reasons Not To Invest In Synairgen:

- Company is small and does not have the power/influence of large pharma.
- Chance of being the 20% that typically fail in P3.
- IFNb never been used in this way before. Could be some unknowns.
- Politics.
- Cost, with vaccines and pills cheaper.
- I own it.

Matml74, another question for you if I may…

Phase 3 is effectively an extension of phase 2, with the same protocols? Data also being checked by Paraxel. If so, could you see a reason why the results wouldn’t be too far away from what we seen in phase2?

Matml74, that’s useful info. I do not know the full process and the intricacies of how this will all work.

I had assumed SNG would have some input into the analysis, not that it would be done entirely by Paraxel? If that is indeed the case, then we are at their mercy and it will indeed by well into January

I’m in until the endgame so whatever way they manage it will not influence when I sell.

Skippy, the 35 days will have passed. To my knowledge it is then how long it takes SNG to analyse the data and get it verified. I assume if Boris wheeled in every expert in the industry to help out, it could be done very quickly. Or at least very high level data (i.e. no one died on SNG001 and can now hold their breath underwater for 30 minutes).

Surely SNG and the government have a moral obligation to get this data read ASAP.

I assumed there wouldn’t be an RNS to say they had safely received the data. But then SNG seem to be posting a few more RNS’s these days. I mean, if they can RNS that they are attending a presentation then one to confirm data received for the most important trial in the company’s history would also do quite nicely ;)

Skippy, again I asked not in development or trials!

Anyway, all this debating means we might miss a little buying opportunity… 185p… Ndn71 - LEAK!!!

But Docdaneeka, how will they kill their mum at Sunday lunch? If she’s had the vaccine then she’s protected, no?

Fruits, not trials.

How many had been approved and used widely (or at all) before Covid?

Not new novel ideas…

Erm Skippy, how many vaccines using mRNA technology have been used before?

Thanks Wyndrum, you beat me to it.